Onconetix, Inc. (ONCO) stock
ONCONasdaqPharmaceutical PreparationsFiscal year ends December 31
$3.15+0.15 (+5.00%)
Close on Nov 18, 2026Market cap $12.44MP/E –Yield –
Onconetix operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Onconetix's operating income for the twelve months ending Jun 30, 2026 was -$16.31M. For fiscal 2025 it was -$17.86M. The highest annual figure on record is -$3.42M in fiscal 2021.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$17.86M | – |
| FY2024 | Dec 31, 2024 | -$56.49M | – |
| FY2023 | Dec 31, 2023 | -$36.03M | – |
| FY2022 | Dec 31, 2022 | -$13.48M | – |
| FY2021 | Dec 31, 2021 | -$3.42M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$2.73M | – |
| Q1 FY2026 | Mar 31, 2026 | -$10.23M | – |
| Q4 FY2025 | Dec 31, 2025 | -$1.28M | – |
| Q3 FY2025 | Sep 30, 2025 | -$2.07M | – |
| Q2 FY2025 | Jun 30, 2025 | -$1.94M | – |
| Q1 FY2025 | Mar 31, 2025 | -$12.57M | – |
| Q4 FY2024 | Dec 31, 2024 | -$29.15M | – |
| Q3 FY2024 | Sep 30, 2024 | -$2.65M | – |
| Q2 FY2024 | Jun 30, 2024 | -$13.62M | – |
| Q1 FY2024 | Mar 31, 2024 | -$11.08M | – |
| Q4 FY2023 | Dec 31, 2023 | -$22.05M | – |
| Q3 FY2023 | Sep 30, 2023 | -$4.49M | – |
| Q4 FY2022 | Dec 31, 2022 | -$3.25M | – |
| Q3 FY2022 | Sep 30, 2022 | -$3.87M | – |
| Q2 FY2022 | Jun 30, 2022 | -$4.29M | – |
| Q1 FY2022 | Mar 31, 2022 | -$2.07M | – |
| Q4 FY2021 | Dec 31, 2021 | -$1.20M | – |
| Q3 FY2021 | Sep 30, 2021 | -$1.10M | – |
| Q2 FY2021 | Jun 30, 2021 | -$792.27K | – |
| Q1 FY2021 | Mar 31, 2021 | -$325.78K | – |
See a number that looks wrong?